Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, PhD, Jeejin Im, June H-J H-J Han, Kyu-Tae Kim, PhD, Jeong-Hyeok Yoon, PhD, Hanna Cho, PhD, Seung-Hye Choi, PhD, David Young, MD, Bao Nguyen, Ruiqi Zhu, PhD, Li Li, MD,PhD, Donald Small, MD, PhD, Taebo Sim, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139044

Published: 2020

Journal Articles

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Atsushi Nonami, Martin Sattler, Ellen Weisberg, Qingsong Liu, Jianming Zhang, Matthew P. Patricelli, Amanda L. Christie, Amy M. Saur, Nancy E. Kohl, Andrew L. Kung, Hojong Yoon, Taebo Sim, Nathanael S. Gray, James D. Griffin

Blood (2015) 125 (20): 3133–3143.

https://doi.org/10.1182/blood-2014-12-615906

Published: 2015

Includes: Supplemental data

Journal Articles

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Jianming Zhang, PhD, Qingsong Liu, PhD, Matthew Patricell, PhD, Hojong Yoon, Amanda L. Christie, B.S., Amy M. Sauer, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S. Gray, PhD, James D. Griffin, MD

Blood (2013) 122 (21): 169.

https://doi.org/10.1182/blood.V122.21.169.169

Published: 2013

Journal Articles

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Liu Qingsong, PhD, Jianming Zhang, PhD, Guillaume Adelmant, PhD, Jarrod A Marto, PhD, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S Gray, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 2455.

https://doi.org/10.1182/blood.V120.21.2455.2455

Published: 2012

Journal Articles

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Blood (2010) 115 (21): 4206–4216.

https://doi.org/10.1182/blood-2009-11-251751

Published: 2010

Includes: Supplemental data

NARROW

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Email alerts

ASH Publications

American Society of Hematology

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only